Tal Wenderow serves as Independent Director of the Company. Since February 2019, Mr. Wenderow serves as the President and CEO of Vocalis Health Inc., an AI healthtech company pioneering the development of vocal biomarkers. Previously, Mr. Wenderow co-founded Corindus Vascular Robotics in 2002, which was a New York Stock Exchange-listed company upon its acquisition by Siemens Healthineers in 2019. Mr. Wenderow held various positions at Corindus from founder, Chief Executive Officer and director at inception, Executive Vice President Product & Business Development to his most recent role as Executive Vice President of International & Business Development. Mr. Wenderow received a B.Sc. in Mechanical Engineering at the Technion – Israel Institute of Technology, Haifa, Israel. The Company believes that Mr. Wenderow is qualified as a Board member of the Company because of his extensive knowledge of the medical robotics space with specific focus on interventional procedures, as well as his medical devices start up experience.
Tal Wenderow is 46, he's been the Independent Director of Microbot Medical Inc since 2020. There are 13 older and no younger executives at Microbot Medical Inc. The oldest executive at Microbot Medical Inc is Prof. Moshe Shoham, 69, who is the Co-Founder, Scientific Director & Member of Scientific Advisory Board.
Tal's mailing address filed with the SEC is C/O MICROBOT MEDICAL INC., 288 GROVE STREET, SUITE 388, BRAINTREE, MA, 02184.
Over the last 8 years, insiders at Microbot Medical Inc have traded over $5,894,432 worth of Microbot Medical Inc stock and bought 10,000 units worth $11,000 . The most active insiders traders include Yoseph Bornstein, Investment Management Ltd A... oraz Moshe Shoham. On average, Microbot Medical Inc executives and independent directors trade stock every 37 days with the average trade being worth of $46,188. The most recent stock trade was executed by Yoseph Bornstein on 19 October 2020, trading 4,881 units of MBOT stock currently worth $38,755.
microbot medical was founded with the vision of pioneering micro invasive surgery, transforming one of the biggest trends in healthcare - minimally invasive surgery (estimated to be close to $20b by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. through its unique platforms, microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. microbot’s virob platform is an autonomous advancing micro robot (aamr), less then 1mm in diameter, which has the ability to advance (forward/bac
Microbot Medical Inc executives and other stock owners filed with the SEC include: